FIN News

Putting people with Fabry first: a talent that Amicus Therapeutics and FIN share. This commonality has ensured a strong partnership, spanning more than 16 years. Amicus Therapeutics is a pharma industry leader advancing the professional field of patient advocacy; it develops and delivers medicine for people living with rare diseases. Jayne C. Gershkowitz, Chief [...]

Fabry disease is rather easy to test for and diagnose, yet there continues to be limited awareness about the disease. Fabry Australia, a FIN member , is on a quest to place it on the national agenda. Sheridan Campbell explains how her organisation raises awareness.  Challenges Oftentimes people exhibit symptoms for many years, without [...]